Latest News
Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 40 mg/10 mL [4 mg/mL]) |
Drug Class | GD2-binding monoclonal antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GMCSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Summary
- Naxitamab-gqgk (Danyelza) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
- Three randomized controlled trials were reviewed. One study specifically examined Danyelza's safety and efficacy, while another focused on GD2/GD3 vaccine as an alternative treatment approach for high-risk neuroblastoma. The third document discussed statins but was not directly comparable as it pertained to a different cancer context.
- In terms of safety profile comparison between Danyelza and GD2/GD3 vaccine, at least 50% of patients experienced various adverse events like pain, hypotension, bronchospasm, etc., when treated with Danyelza. However, these adverse effects were generally manageable through premedications and supportive therapies, whereas the GD2/GD3 vaccine had self-limited injection-associated local reactions without any > grade 3 toxicities reported.
- Direct comparison of efficacy between Danyelza and other treatments within these studies is challenging due to a lack of detailed outcome data for naxitamab-gqgk; however, the continuation of its clinical trial suggests promising results compared to the clear survival benefits presented by the GD2/GD3 Vaccine study, which showed a progression-free survival rate at five years being around 32% ±6%, indicating significant impact on patient outcomes.
- Management protocols are emphasized, particularly regarding early recognition and management of infusion-related AEs during the administration of naxitamab-gqgk. Highlighting the importance of outpatient care adjustments, education of both patients and caregivers is essential for ensuring better handling of potential side-effects, thereby improving the overall effectiveness of the drug regimen.
- The relevance of the second document discussing statins is indirect at best, underscoring the contextual limitations of cross-study comparisons in this specific inquiry.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Danyelza (naxitamab-gqgk) Prescribing Information. | 2024 | Y-mAbs Therapeutics, Inc., New York, NY |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events. | Data not availableSubjects F: null% M: null% | 2023 | Cancer Reports |
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB). | Data not availableSubjects F: null% M: null% | 2020 | Journal of Clinical Oncology |
Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression. | Data not availableSubjects F: null% M: null% | 2020 | Journal of Clinical Oncology |
Sex Distribution:
Year:
2023
Source:Cancer Reports
Sex Distribution:
Year:
2020
Source:Journal of Clinical Oncology
Sex Distribution:
Year:
2020
Source:Journal of Clinical Oncology